Journal Scans
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
Anti-Emesis: IV Fosaprepitant Noninferior to Oral Aprepitant
S Grunberg, D Chua, A Maru, J Dinis, S Devandry, JA Boice, JS Hardwick, E Beckford, A Taylor, A Carides, F Roila, J Herrstedt
Yes
20110207
2011 Mar 7
J Clin Oncol
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
J Clin Oncol. 2011 Mar 7;[Epub Ahead of Print], S Grunberg, D Chua, A Maru, J Dinis, S Devandry, JA Boice, JS Hardwick, E Beckford, A Taylor, A Carides, F Roila, J Herrstedt
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Chemotherapy-induced nausea and vomiting (CINV) is a common significant adverse event of chemotherapy. The addition of the NK-1 receptor antagonist aprepitant to a 3-day regimen with a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist and dexamethasone has been shown to improve prevention of CINV during the 120 hours after initiation of chemotherapy (overall phase; OP). Fosaprepitant dimeglumine is an analog of aprepitant, and is rapidly converted to aprepitant after intravenous (IV) administration....
